Studies performed since the last competitive renewal have demonstrated the feasibility of pursuing antigen-specific T cell therapy for treatment of human disease. Methods were developed for isolating and efficiently expanding in vitro CD4+ and CD8+ T cells clones with retention of normal function, and, in a Phase I trail; the adoptive transfer of large numbers of cloned CD8+ T cells specific for CMV was demonstrated to be non-toxic and to reconstitute deficient CD8+ T cell responses to CMV in immunodeficient bone marrow transplant (BMT) recipients. No patient with restored CD8+ T cell immunity developed CMV viremia or disease. In this project, we propose to use this T cell culture technology to determine if adoptive transfer of CMV-specific T cell clones can prevent early and late CMV infection in BMT recipients, and avoids toxicities associated with drug therapy. Several human tumors have been identified that express potentially immunogenic proteins. These include virus-associated malignancies, which provide attractive targets for immunologic therapies, since the viral proteins represent tumor-specific antigens. A subset of patients with Hodgkin's disease express several EBV latent proteins in their tumor cells, and studies are proposed to treat this human malignancy with EBV-specific T cell clones.
The specific aims are: 1) to perform a Phase II study of adoptive immunotherapy with CMV-specific T cell clones as prophylaxis for CMV disease in recipients of allogeneic BMT from HLA-matched family members -- the study will include transfer of both cytolytic CD8+ and helper CD4= T cell clones and will examine therapeutic efficacy, immunologic reconstitution, and reduction in the frequency of neutropenia, a toxicity associated with ganciclovir prophylaxis; 2) to perform a Phase II study of adoptive immunotherapy with CMV-specific T cell clones for prevention of late CMV disease (> day + 100 post- BMT) in recipients of allogeneic BMT from HLA-matched unrelated donors--the study will evaluate therapeutic efficacy, long-term immunologic reconstitution, and the feasibility of generating T cells for therapy from unrelated donors; and 3) to evaluate the feasibility safety, and potential efficacy of treating Hodgkin's disease patients with EBV+ tumors by adoptive transfer of CD8+ T cell clones reactive with the EBV-encoded LMP1 or LMP2 proteins expressed in Reed- Sternberg cells -- this pilot study will examine safety, persistence, localization of transferred CD8+ clones to sites of tumor, and potential antitumor activity in patients undergoing autologous or allogeneic BMT for relapsed/resistant Hodgkins' disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA018029-26
Application #
6420503
Study Section
Project Start
2001-02-13
Project End
2001-11-30
Budget Start
Budget End
Support Year
26
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
McCune, Jeannine S; Storer, Barry; Thomas, Sushma et al. (2018) Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biol Blood Marrow Transplant 24:1802-1807
Deegan, Anthony J; Talebi-Liasi, Faezeh; Song, Shaozhen et al. (2018) Optical coherence tomography angiography of normal skin and inflammatory dermatologic conditions. Lasers Surg Med 50:183-193
Leger, Kasey J; Baker, K Scott; Cushing-Haugen, Kara L et al. (2018) Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer 124:1507-1515
Schmitt, Michael W; Pritchard, Justin R; Leighow, Scott M et al. (2018) Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. Clin Cancer Res 24:5321-5334
Shaw, Bronwen E; Syrjala, Karen L; Onstad, Lynn E et al. (2018) PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. Cancer 124:841-849
Jamani, Kareem; Onstad, Lynn E; Bar, Merav et al. (2018) Quality of Life of Caregivers of Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2271-2276
Ogimi, Chikara; Xie, Hu; Leisenring, Wendy M et al. (2018) Initial High Viral Load Is Associated with Prolonged Shedding of Human Rhinovirus in Allogeneic Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2160-2163
Salter, Alexander I; Pont, Margot J; Riddell, Stanley R (2018) Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood 131:2621-2629
Lee, Stephanie J; Nguyen, Tam D; Onstad, Lynn et al. (2018) Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:555-562
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313

Showing the most recent 10 out of 1845 publications